Printer Friendly

SYSTEMIX REPORTS HIV FINDING IN 'NATURE'

 PALO ALTO, Calif., June 24 /PRNewswire/ -- SyStemix, Inc. (NASDAQ: STMX) announced the publication of an article, titled "HIV Induces Thymus Depletion In Vivo," appearing today in the July edition of the scientific journal, Nature. SyStemix' scientists showed in the SCID-hu mouse model that HIV can destroy developing T cells in the human thymus. T cells are important in fighting viral infections and are among the cells most vulnerable to HIV infection.
 The experiments also indicated that HIV destroys the immune systems' ability to generate new T cells and thus the virus does not allow for the regeneration of an otherwise destroyed circulating T cell pool. These findings are important steps forward in understanding the ways in which HIV causes disease and therefore developing effective therapies.
 SyStemix proprietary SCID-hu mouse is the only animal model available to study HIV infection in the setting of human organs. The animal model is constructed by implanting fragments of human organs into the immunodeficient SCID mouse. SyStemix' scientists demonstrated, in this most recent study, that the SCID-hu mouse not only serves to validate known observations about the human immune system but can also be used to uncover previously undefined mechanisms by which HIV compromises the immune system.
 "The publication of this article validates SyStemix' approach to the development of viable therapies to treat infection and prevent replication of the AIDS virus," said Linda Sonntag, Ph.D., president and CEO of SyStemix. "We are currently using the SCID-hu mouse to study chemotherapies for AIDS, gene therapy of AIDS and cellular therapies as adjuncts for cancer chemotherapy."
 The authors of the paper are Mark Bonyhadi, Ph.D., Linda Rabin, M.S., Suzan Salimi, M.S., Joseph M. McCune, M.D., Ph.D. and Hideto Kaneshima, M.D., Ph.D. from SyStemix as well as Daniel Brown, M.A., and Jon Kosek, M.D., from the Veterans Administration Hospital of Palo Alto.
 SyStemix, Inc. based in Palo Alto, is primarily engaged in the development of cellular processes and products based on human hematopoietic stem cells, human megakaryocytes and megkaryocyte progenitors.
 -0- 6/24/93
 /CONTACT: Linda Sonntag, Ph.D., president and CEO of SyStemix, Inc. 415-813-6510, or Anthony J. Russo, Ph.D., of Noonan Russo Communications Inc., 212-979-9180/


CO: SyStemix, Inc. ST: California IN: MTC SU:

LR-SM -- NY012 -- 5201 06/24/93 09:42 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 24, 1993
Words:387
Previous Article:VITAL HEART SYSTEMS, INC. ANNOUNCES VERY SUCCESSFUL LAUNCH OF VITAL HEART CHECKPOINT CENTERS
Next Article:MITCHELL REPORTS FOUR LIMESTONE COUNTY PRODUCERS
Topics:


Related Articles
SYSTEMIX ANNOUNCES THIRD QUARTER RESULTS
SYSTEMIX REPORTS THE PUBLICATION OF TWO MAJOR SCIENTIFIC ARTICLES
SYSTEMIX REPORTS THE PUBLICATION OF TWO MAJOR SCIENTIFIC ARTICLES
SYSTEMIX ENTERS JOINT VENTURE WITH SANDOZ FOR GENE THERAPY AGAINST HIV
SYSTEMIX REPORTS FOURTH QUARTER AND TWELVE MONTHS RESULTS
SYSTEMIX REPORTS SECOND QUARTER AND SIX MONTH RESULTS
SYSTEMIX PRESIDENT/CEO RESIGNS
SYSTEMIX ANNOUNCES ITS U.S. PHASE I/II CLINICAL TRIALS
SYSTEMIX' DISEASE-FREE STEM CELL TRANSPLANTS MAY CONTRIBUTE TO IMMUNE SYSTEM RECOVERY
Wake Forest Scientists Find Way To Short-Circuit Initial HIV Invasion

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters